BACKGROUND: Relevant preclinical models are necessary for further mechanistic and translational studies of c-kit+ cardiac stem cells (CSCs). The present study was undertaken to determine whether intracoronary CSCs are beneficial in a porcine model of chronic ischemic cardiomyopathy. METHODS AND RESULTS: Pigs underwent a 90-minute coronary occlusion followed by reperfusion. Three months later, autologous CSCs (n=11) or vehicle (n=10) were infused into the infarct-related artery. At this time, all indices of left ventricular (LV) function were similar in control and CSC-treated pigs, indicating that the damage inflicted by the infarct in the 2 groups was similar; 1 month later, however, CSC-treated pigs exhibited significantly greater LV ejection fraction (echocardiography) (51.7±2.0% versus 42.9±2.3%, P<0.01), systolic thickening fraction in the infarcted LV wall, and maximum LV dP/dt, as well as lower LV end-diastolic pressure. Confocal microscopy showed clusters of small α-sarcomeric actin-positive cells expressing Ki67 in the scar of treated pigs, consistent with cardiac regeneration. The origin of these cycling myocytes from the injected cells was confirmed in 4 pigs that received enhanced green fluorescent protein -labeled CSCs, which were positive for the cardiac markers troponin I, troponin T, myosin heavy chain, and connexin-43. Some engrafted CSCs also formed vascular structures and expressed α-smooth muscle actin. CONCLUSIONS: Intracoronary infusion of autologous CSCs improves regional and global LV function and promotes cardiac and vascular regeneration in pigs with old myocardial infarction (scar). The results mimic those recently reported in humans (Stem Cell Infusion in Patients with Ischemic CardiOmyopathy [SCIPIO] trial) and establish this porcine model of ischemic cardiomyopathy as a useful and clinically relevant model for studying CSCs.
BACKGROUND: Relevant preclinical models are necessary for further mechanistic and translational studies of c-kit+ cardiac stem cells (CSCs). The present study was undertaken to determine whether intracoronary CSCs are beneficial in a porcine model of chronic ischemic cardiomyopathy. METHODS AND RESULTS:Pigs underwent a 90-minute coronary occlusion followed by reperfusion. Three months later, autologous CSCs (n=11) or vehicle (n=10) were infused into the infarct-related artery. At this time, all indices of left ventricular (LV) function were similar in control and CSC-treated pigs, indicating that the damage inflicted by the infarct in the 2 groups was similar; 1 month later, however, CSC-treated pigs exhibited significantly greater LV ejection fraction (echocardiography) (51.7±2.0% versus 42.9±2.3%, P<0.01), systolic thickening fraction in the infarcted LV wall, and maximum LV dP/dt, as well as lower LV end-diastolic pressure. Confocal microscopy showed clusters of small α-sarcomeric actin-positive cells expressing Ki67 in the scar of treated pigs, consistent with cardiac regeneration. The origin of these cycling myocytes from the injected cells was confirmed in 4 pigs that received enhanced green fluorescent protein -labeled CSCs, which were positive for the cardiac markers troponin I, troponin T, myosin heavy chain, and connexin-43. Some engrafted CSCs also formed vascular structures and expressed α-smooth muscle actin. CONCLUSIONS: Intracoronary infusion of autologous CSCs improves regional and global LV function and promotes cardiac and vascular regeneration in pigs with old myocardial infarction (scar). The results mimic those recently reported in humans (Stem Cell Infusion in Patients with Ischemic CardiOmyopathy [SCIPIO] trial) and establish this porcine model of ischemic cardiomyopathy as a useful and clinically relevant model for studying CSCs.
Authors: Kai C Wollert; Gerd P Meyer; Joachim Lotz; Stefanie Ringes-Lichtenberg; Peter Lippolt; Christiane Breidenbach; Stephanie Fichtner; Thomas Korte; Burkhard Hornig; Diethelm Messinger; Lubomir Arseniev; Bernd Hertenstein; Arnold Ganser; Helmut Drexler Journal: Lancet Date: 2004 Jul 10-16 Impact factor: 79.321
Authors: Birgit Assmus; Volker Schächinger; Claudius Teupe; Martina Britten; Ralf Lehmann; Natascha Döbert; Frank Grünwald; Alexandra Aicher; Carmen Urbich; Hans Martin; Dieter Hoelzer; Stefanie Dimmeler; Andreas M Zeiher Journal: Circulation Date: 2002-12-10 Impact factor: 29.690
Authors: Federico Quaini; Konrad Urbanek; Antonio P Beltrami; Nicoletta Finato; Carlo A Beltrami; Bernardo Nadal-Ginard; Jan Kajstura; Annarosa Leri; Piero Anversa Journal: N Engl J Med Date: 2002-01-03 Impact factor: 91.245
Authors: Kimberlee M Fischer; Christopher T Cottage; Weitao Wu; Shabana Din; Natalie A Gude; Daniele Avitabile; Pearl Quijada; Brett L Collins; Jenna Fransioli; Mark A Sussman Journal: Circulation Date: 2009-11-09 Impact factor: 29.690
Authors: Francisco Fernández-Avilés; José Alberto San Román; Javier García-Frade; María Eugenia Fernández; María Jesús Peñarrubia; Luis de la Fuente; Manuel Gómez-Bueno; Alberto Cantalapiedra; Jesús Fernández; Oliver Gutierrez; Pedro L Sánchez; Carolina Hernández; Ricardo Sanz; Javier García-Sancho; Ana Sánchez Journal: Circ Res Date: 2004-09-09 Impact factor: 17.367
Authors: P Richard Vulliet; Melanie Greeley; S Mitchell Halloran; Kristin A MacDonald; Mark D Kittleson Journal: Lancet Date: 2004-03-06 Impact factor: 79.321
Authors: S Windmolders; L Willems; A Daniëls; L Linsen; Y Fanton; M Hendrikx; R Koninckx; J-L Rummens; K Hensen Journal: Cell Prolif Date: 2015-01-29 Impact factor: 6.831
Authors: Joshua K Salabei; Pawel K Lorkiewicz; Candice R Holden; Qianhong Li; Kyung U Hong; Roberto Bolli; Aruni Bhatnagar; Bradford G Hill Journal: Stem Cells Date: 2015-05-26 Impact factor: 6.277
Authors: Matthew C L Keith; Yukichi Tokita; Xian-Liang Tang; Shahab Ghafghazi; Joseph B Moore; Kyung U Hong; Julius B Elmore; Alok R Amraotkar; Haixun Guo; Brian L Ganzel; Kendra J Grubb; Michael P Flaherty; Bathri N Vajravelu; Marcin Wysoczynski; Roberto Bolli Journal: Basic Res Cardiol Date: 2015-07-07 Impact factor: 17.165